Our medicines

We believe in the power of science to tackle some of the most challenging diseases of our time. We have a long history of developing life-saving medicines and a promising pipeline to shape the next generation of treatment options across multiple indications and in 4 therapeutic areas.

Report side effects/adverse reactions or product quality complaints

E-mail: medischeafdeling@bms.com

Risk management and Pregnancy Prevention Program

For information and questions about risk management regarding Bristol Myers Squibb products and the Pregnancy Prevention Program, please contact Bristol Myers Squibb's Patient Safety Department at:

E-mail: safety_netherlands@bms.com

Phone: +31 (0)30 300 2222

This list gives an overview of the reimbursed drugs of Bristol Myers Squibb in the Netherlands in December 2021.

ABRAXANE (paclitaxel)

BARACLUDE (entecavir)

ELIQUIS (apixaban)

EMPLICITI (elotuzumab)

IMNOVID (pomalidomide)

KENACORT A-10 (triamcinolonacetonide)

KENACORT A-40 (triamcinolonacetonide)

NULOJIX (belatacept)

OPDIVO (nivolumab)

OPDUALAG (nivolumab and relatlimab)

ORENCIA 250 mg powder for concentrate for solution for infusion (abatacept)

ORENCIA 125 mg solution for injection in a pre-filled syringe (abatacept)

ORENCIA 125 mg oplossing voor injectie in een voorgevulde pen (abatacept)

REBLOZYL (luspatercept)

REVLIMID (lenalidomide)

REYATAZ (atazanavir)

SPRYCEL (dasatinib)

VIDAZA (azacitidine)

YERVOY (ipilimumab)

ZEPOSIA (ozanimod)